Wholesale
Wholesale pricing available
Qualify for automatic discounts at checkout when your order of wholesale eligible items hits a volume threshold.
$2,000+15% off$4,000+20% off$6,000+25% off$10,000+40% offFull wholesale details →
$712.17$749.65
($142.43 / Item) — Save $37.48 (5% off)
In stock — dispatches within 24h, tracked
GLP-2 TRZ 10mg. Used to support weight loss, appetite control, reduced food cravings, and improved blood sugar management. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDepends on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
Wholesale pricingCost per item by order value
$2,000+15% off$605.34per item
$4,000+20% off$569.74per item
$6,000+25% off$534.13per item
$10,000+40% off$427.30per item
Estimated prices based on the current product or selected option price. Tiers use your eligible wholesale subtotal before the wholesale discount. Discounts apply automatically in your cart.
Choose an option to see its wholesale prices.
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-2 TRZ is a dual incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) receptors. The dual GIP/GLP-1 mechanism that distinguishes this compound class from single receptor GLP-1 agonists like Semaglutide and from triple receptor agonists like GLP-3 RTA. Hudson Science’s standalone 10mg lyophilized vial delivers the lowest concentration single unit GLP-2 TRZ presentation in CSD’s range, suited to researchers initiating dual incretin agonist protocols, evaluating compound performance before committing to higher concentration supply, or requiring a single vial for shorter duration research designs where the 20mg and 30mg vial concentrations exceed protocol compound requirements.
The 10mg single vial occupies the entry point position in CSD’s GLP-2 TRZ concentration range: below the 20mg and 30mg lyophilized vial variants and complemented by the GLP-2 TRZ 10mg Complete Kit which supplies the same vial alongside bacteriostatic water, syringes, needles, and alcohol wipes for researchers requiring a fully equipped preparation system alongside the compound. For researchers who already have reconstitution supplies and administration accessories, the standalone 10mg vial provides the same compound entry point without the additional kit components; a straightforward procurement option for laboratories with existing research infrastructure.
The dual GLP-1 and GIP receptor co activation mechanism remains consistent across all GLP-2 TRZ presentations. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, gastric emptying delay, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic effects and bone turnover research dimensions. The combined dual receptor profile producing a synergistic incretin response that has made dual incretin agonist compounds among the most actively researched peptide classes in contemporary metabolic and endocrine science.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s dual incretin agonist range spans: GLP-2 TZ 15mg, GLP-2 TRZ 10mg standalone vial, GLP-2 TRZ 10mg Complete Kit, GLP-2 TRZ 20mg, GLP-2 TRZ 30mg, and the GLP-2 TRZ 40mg adjustable dose pen. Giving researchers the most comprehensive dual incretin agonist format and concentration selection available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside GLP-1 receptor agonist compounds and triple incretin agonists in comparative incretin pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
GLP-2 TRZ contains 10mg of TRZ, a long acting peptide that simultaneously activates glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP 1) receptors. TRZ has been extensively studied in metabolic research involving glucose regulation, insulin sensitivity, appetite signaling, body weight regulation, and broader cardiometabolic function. This product contains 10mg of lyophilized TRZ in a single vial.
TRZ has been extensively investigated in research involving type 2 diabetes, obesity, body weight regulation, glucose control, insulin sensitivity, appetite, and metabolic health. Its dual GIP and GLP-1 receptor activity allows researchers to study two complementary incretin pathways involved in glucose dependent insulin secretion, food intake regulation, and metabolic signaling.
TRZ activates both GIP and GLP-1 receptors. These incretin receptors participate in glucose dependent insulin secretion and metabolic regulation, while GLP-1 receptor activity also contributes to appetite and food intake signaling. TRZ was engineered as a single long acting molecule capable of activating both receptor systems.
The primary difference is receptor activity. Semaglutide primarily activates the GLP-1 receptor, while TRZ activates both GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1, and glucagon receptors. TRZ therefore represents a dual receptor incretin approach compared with the single receptor profile of semaglutide and triple receptor profile of retatrutide.
Yes! This batch is HPLC tested to verify TRZ identity and content accuracy at 10mg per vial. A certificate of analysis is available.
